These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 9365601

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Impact of immunosuppression in liver transplantation across a positive crossmatch.
    Lang M, Neumann U, Knoop M, Bechstein WO, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1466-7. PubMed ID: 9636595
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic.
    Pirsch JD.
    Transplant Proc; 1998 Aug; 30(5):2223-5. PubMed ID: 9723448
    [No Abstract] [Full Text] [Related]

  • 48. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.
    Bush WW.
    AACN Clin Issues; 1999 May; 10(2):253-69; quiz 304-6. PubMed ID: 10578712
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients.
    Millis JM, Bruce DS, Newell KA, Piper JB, Woodle ES, Seaman DS, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR.
    Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Klupp J, Glanemann M, Junge G, Pfitzmann R, Bahra M, Radtke C, Neumann U, Neuhaus R, Neuhaus P.
    Clin Transplant; 2006 Apr; 20(3):272-83. PubMed ID: 16824141
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Mycophenolate mofetil in comparison with other immunosuppressive drugs].
    Schnülle P, van der Woude FJ.
    Internist (Berl); 1998 Aug; 39(8):879-86. PubMed ID: 9757398
    [No Abstract] [Full Text] [Related]

  • 57. Mycophenolate mofetil for prevention of acute rejection.
    Moore R, Griffin P, Darby C, Jurewicz A, Lord R.
    Lancet; 1995 Jul 22; 346(8969):253. PubMed ID: 7616827
    [No Abstract] [Full Text] [Related]

  • 58. Impact of immunosuppressive therapy on recurrence of hepatitis C.
    Everson GT.
    Liver Transpl; 2002 Oct 22; 8(10 Suppl 1):S19-27. PubMed ID: 12362294
    [Abstract] [Full Text] [Related]

  • 59. Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft.
    Tang S, Lai KN.
    Am J Kidney Dis; 2005 Apr 22; 45(4):A55, e61-2. PubMed ID: 15806458
    [No Abstract] [Full Text] [Related]

  • 60. Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late?
    Beckebaum S, Cicinnati VR.
    Dig Dis Sci; 2011 Jan 22; 56(1):4-6. PubMed ID: 21049289
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.